Literature DB >> 34428588

lncRNA ADAMTS9-AS1 promotes bladder cancer cell invasion, migration, and inhibits apoptosis and autophagy through PI3K/AKT/mTOR signaling pathway.

Guoqing Yang1, Zijian Li2, Lizhi Dong3, Fan Zhou4.   

Abstract

Bladder cancer is the most common cancer in the urinary system which has threatened lives. Increasing evidence has shown that lncRNAs were expressed in cancer cells as a biomarker and might regulate cancer cell development and progression. It was reported that ADAMTS9-AS1 plays a suppressive role in tumor cell growth and proliferation in prostate cancer. However, it remains unclear whether ADAMTS9-AS1 influences the function of bladder cancer cells. In this study, we detected that ADAMTS9-AS1 is highly expressed in bladder cancer. We observed that the up-regulation of ADAMTS9-AS1 promoted cell proliferation, migration and invasion, and reduced the apoptosis and autophagy of 5637 and T42 cell lines. Meanwhile, the down-regulation of ADAMTS9-AS1 increased the apoptosis and autophagy, and suppressed their proliferation, migration and invasion. Interestingly, the up-regulation of ADAMTS9-AS1 was accompanied by the activation of PI3K/AKT/mTOR signaling pathway, while the down-regulation of ADAMTS9-AS1 lead to an opposite effect. Together, these results demonstrated that ADAMTS9-AS1 promotes bladder cancer cell invasion and migration, and negatively regulates bladder cancer cell apoptosis and autophagy, which might be through PI3K/AKT/mTOR signaling pathway. Targeting ADAMTS9-AS1 might become a potential therapeutic approach in treating bladder cancer.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  ADAMTS9-AS1; Apoptosis and autophagy; Bladder cancer; PI3K/AKT/mTOR signaling pathway

Mesh:

Substances:

Year:  2021        PMID: 34428588     DOI: 10.1016/j.biocel.2021.106069

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  7 in total

1.  TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.

Authors:  Ming Chi; Jiao Liu; Chenxue Mei; Yaxing Shi; Nanqi Liu; Xuefeng Jiang; Chang Liu; Xun Sun; Bo Yin; Xin Meng; Biao Wang; Nan Xue; Hong Hong; Jisheng Xie
Journal:  J Exp Clin Cancer Res       Date:  2022-05-17

2.  Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration.

Authors:  Zhongbao Zhou; Yongjian Zhou; Xin Zhou; Yongjin Huang; Yuanshan Cui; Yong Zhang
Journal:  J Oncol       Date:  2022-06-28       Impact factor: 4.501

3.  Astragalus-Scorpion Drug Pair Inhibits the Development of Prostate Cancer by Regulating GDPD4-2/PI3K/AKT/mTOR Pathway and Autophagy.

Authors:  Xujun You; Yongrong Wu; Qixin Li; Wen Sheng; Qing Zhou; Wei Fu
Journal:  Front Pharmacol       Date:  2022-06-29       Impact factor: 5.988

4.  Circular RNA_0000326 promotes bladder cancer progression via microRNA-338-3p/ETS Proto-Oncogene 1/phosphoinositide-3 kinase/Akt pathway.

Authors:  Yong Chen; Dong Wang; Tao Shu; Kangwei Sun; Jianbo Zhao; Min Wang; Yi Huang; Ping Wang; Hang Zheng; Zhixuan Cai; Zengyue Yang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  PRRX1/FOXM1 reduces gemcitabin-induced cytotoxicity by regulating autophagy in bladder cancer.

Authors:  Xixi Huang; Weiping Huang; Keming Wu; Qi Lin; Gang Chen
Journal:  Transl Androl Urol       Date:  2022-08

6.  Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma.

Authors:  Cheng Zeng; Yu Liu; Rong He; Xiaohuan Lu; Yuyang Dai; Guoping Qi; Jingsong Liu; Jianzhong Deng; Wenbin Lu; Jianhua Jin; Qian Liu
Journal:  Front Genet       Date:  2022-08-25       Impact factor: 4.772

Review 7.  Long Noncoding RNAs and Circular RNAs Regulate AKT and Its Effectors to Control Cell Functions of Cancer Cells.

Authors:  Jen-Yang Tang; Ya-Ting Chuang; Jun-Ping Shiau; Kun-Han Yang; Fang-Rong Chang; Ming-Feng Hou; Ammad Ahmad Farooqi; Hsueh-Wei Chang
Journal:  Cells       Date:  2022-09-20       Impact factor: 7.666

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.